Literature DB >> 14997011

Modulation of brain insulin-like growth factor I (IGF-I) binding sites and hypothalamic GHRH and somatostatin levels by exogenous growth hormone and IGF-I in juvenile rats.

Rina Eshet1, Irit Gil-Ad, Olga Apelboym, Yael Segev, Moshe Phillip, Haim Werner.   

Abstract

The effect of exogenous growth hormone (GH) and insulin-like growth factor I (IGF-I) on brain IGF-I binding sites (IGF-IR), and on the levels of growth hormone-releasing hormone (GHRH) and somatostatin was studied in hypophysectomized and intact juvenile male rats. Animals were injected subcutaneously twice daily (n = 5 each) with recombinant GH (rGH) (2.5 U/kg per day) or rIGF-I (500 microg/kg per day). In the hypophysectomized rats, serum GH and IGF-I levels were markedly suppressed and IGF-I levels were partially restored by GH treatment. There was a significant increase in IGF-IR binding capacity in the IGF-I-treated hypophysectomized rats compared to the saline-treated hypophysectomized animals (150.61 +/- 45.66 vs 41.32 +/- 12.42 fmol/mg, p < 0.05) but no significant difference in IGF-IR mRNA levels. GHRH levels in the saline-treated hypophysectomized group were significantly lower than in the saline-treated intact rats (31.2 +/- 11.2 vs 140.6 +/- 48.1 pg/mg tissue, respectively, p < 0.01); no effect was induced by GH or IGF-I (37.5 +/- 26.8 and 53.8 +/- 22.5 pg/mg tissue, respectively). However, in the intact rats, GH and IGF-I injection led to a decrease in GHRH content, which was significant in the GH-treated compared to the saline-treated animals (33.1 +/- 16.2 vs 140.6 +/- 48.1 pg/mg tissue, p < 0.01). No difference was found in somatostatin levels between intact and hypophysectomized rats (631.2 +/- 81.2 and 625.0 +/- 62.5 pg/mg tissue, respectively). However, in the hypophysectomized animals, GH and IGF-I treatment induced a significant increase in somatostatin levels (1300 +/- 193.7 pg/mg tissue, p < 0.01, and 912.5 +/- 81.2 pg/mg tissue, p < 0.05, respectively). Our findings suggest that the bioavailability of exogenous IGF-I is greater than that of GH-stimulated endogenous IGF-I. Because IGF-I is a potent neurotrophic agent, this effect may have important implications for states of neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14997011     DOI: 10.1385/JMN:22:3:179

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  43 in total

Review 1.  Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations.

Authors:  W H Daughaday; P Rotwein
Journal:  Endocr Rev       Date:  1989-02       Impact factor: 19.871

2.  Transient IGF-I gene expression during the maturation of functionally related central projection neurons.

Authors:  C A Bondy
Journal:  J Neurosci       Date:  1991-11       Impact factor: 6.167

3.  Insulin-like growth factor (IGF) and IGF-binding proteins: comparison of human serum and lymph.

Authors:  M Binoux; P Hossenlopp
Journal:  J Clin Endocrinol Metab       Date:  1988-09       Impact factor: 5.958

Review 4.  Endocrine/paracrine interactions following administration of insulin-like growth factor I.

Authors:  P D Gluckman; A A Butler
Journal:  Acta Paediatr Suppl       Date:  1994-04

5.  Recombinant human insulin-like growth factor I induces its own specific carrier protein in hypophysectomized and diabetic rats.

Authors:  J Zapf; C Hauri; M Waldvogel; E Futo; H Häsler; K Binz; H P Guler; C Schmid; E R Froesch
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

6.  Insulin-like growth factor-I and II receptor expression in rat colon mucosa are affected by dietary lipid intake.

Authors:  W Zhang; W H Thornton; R S MacDonald
Journal:  J Nutr       Date:  1998-02       Impact factor: 4.798

7.  Intracerebral administration of insulin-like growth factor I decreases circulating growth hormone levels in the fetal pig.

Authors:  G S Spencer; A A Macdonald; H L Buttle; L G Moore; S S Carlyle
Journal:  Acta Endocrinol (Copenh)       Date:  1991-05

8.  Human growth hormone and somatomedin C suppress the spontaneous release of growth hormone in unanesthetized rats.

Authors:  H Abe; M E Molitch; J J Van Wyk; L E Underwood
Journal:  Endocrinology       Date:  1983-10       Impact factor: 4.736

9.  Insulin-like growth factor-1 receptors in human spinal cord: changes in amyotrophic lateral sclerosis.

Authors:  A Adem; J Ekblom; P G Gillberg; S S Jossan; A Höög; B Winblad; S M Aquilonius; L H Wang; V Sara
Journal:  J Neural Transm Gen Sect       Date:  1994

10.  Expression and regulation of insulin-like growth factor-I (IGF-I) and IGF-binding protein messenger ribonucleic acid levels in tissues of hypophysectomized rats infused with IGF-I and growth hormone.

Authors:  M A Gosteli-Peter; K H Winterhalter; C Schmid; E R Froesch; J Zapf
Journal:  Endocrinology       Date:  1994-12       Impact factor: 4.736

View more
  1 in total

1.  Mifepristone inhibits IGF-1 signaling pathway in the treatment of uterine leiomyomas.

Authors:  Qi Shen; Shuangwei Zou; Bo Sheng; Menghuang Zhao; Lu-Zhe Sun; Xueqiong Zhu
Journal:  Drug Des Devel Ther       Date:  2019-09-03       Impact factor: 4.162

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.